Investment Thesis
Regen BioPharma exhibits severe financial distress with negative stockholders' equity of -6.6M, indicating technical insolvency. The company faces an acute liquidity crisis with only 4.6K in cash against 6.8M in liabilities and a current ratio of 0.03x, while continuing to burn 197.9K in operating cash flow with near-zero revenue generation of 59.1K.
Strengths
- Minimal revenue base provides potential runway for operational restructuring
- No explicit long-term debt obligations limiting structured default risk
- Small operating cost structure reduces absolute capital requirements for survival
Risks
- Negative shareholders' equity of -6.6M indicates technical insolvency and negative book value
- Critical liquidity crisis: 4.6K cash against 6.8M liabilities with 0.03x current ratio suggests imminent solvency risk
- Severe cash burn of 197.9K operating cash flow with stalled revenue at 59.1K (0% YoY growth) creates unsustainable funding gap
- Net losses deteriorating sharply at -967.9K with -90.7% YoY decline indicating worsening operational performance
- No insider activity in past 90 days suggests complete loss of management confidence
- Extreme negative margins (-933.9% operating, -1638.6% net) indicate fundamental business model failure
Key Metrics to Watch
- Cash runway and days of liquidity remaining before insolvency
- Revenue growth rate and product commercialization milestones
- Monthly operating cash burn trend and path to cash flow break-even
- Stockholders' equity trajectory and debt restructuring activities
- Insider transactions as indicator of management confidence
- Quarterly net loss magnitude and operating expense reduction progress
Financial Metrics
Revenue
59.1K
Net Income
-967.9K
EPS (Diluted)
$-0.01
Free Cash Flow
-197.9K
Total Assets
237.1K
Cash
4.6K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-933.9%
Net Margin
-1,638.6%
ROE
N/A
ROA
-408.2%
FCF Margin
-335.1%
Balance Sheet & Liquidity
Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
2,872.5%
Interest Coverage
-15.84x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-09T03:30:23.838977 |
Data as of: 2025-12-31 |
Powered by Claude AI